Current Role of Cytoreductive Nephrectomy
Part 1: Introduction
Part 2: Upfront Cytoreductive Nephrectomy
Part 3: Pre-surgical Systemic Therapy Followed by Delayed Nephrectomy for Metastatic
Renal Cell Carcinoma
Part 4: How Does Cytoreductive Nephrectomy Help?
This activty has expired. Please visit our Online CME Index for more CME offerings.
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Description
Cytoreductive nephrectomy has been a standard of care in metastatic kidney cancer patients since the results of two large randomized trials showed the benefits of this approach in patients subsequently treated with interferon alpha. As more effective systemic therapy has entered the treatment of metastatic RCC, the role of cytoreductive nephrectomy has been re-examined. This webcast will describe the existing data as it applies to the modern treatment era for the current role of this approach in the management of patients with metastatic RCC. The science and biology behind this approach will be reviewed as well as discussion of ongoing research us in the evolving field.
Objectives
At the conclusion of this activity, the participant will be able to:
- Describe the current role of cytoreductive nephrectomy in the management of patients with metastatic RCC.
- Review the ongoing research into the role of pre-surgical systemic therapy followed by delayed nephrectomy in the management of metastatic RCC.
- Review the scientific evidence in support of tumor volume reduction surgery.
Target Audience
This activity is directed to medical oncologists and urologists.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of XXX AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director(s)
Brian Rini, MD |
Planning Committee
Thomas Hutson, D.O., PharmD. |
Christopher Wood, M.D., FACS |
Moderator
Thomas Hutson, D.O., PharmD. |
Faculty
Tsung Wen Chong, MD |
Kimryn Rathmell, MD |
Christopher Wood, M.D., FACS |
Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:
| Thomas Hutson, MD | |||
| Consulting; Teaching & Speaking; Membership on advisory committee or
review panels: |
Bayer; Pfizer; Wyeth | ||
| Independent Contractor: | Bayer; GSK; Pfizer; Wyeth | ||
| Kimryn Rathmell, MD | |||
| Membership on advisory committee or review panels: |
Bayer/Onyx; Pfizer; Wyeth | ||
| Teaching & Speaking: | Pfizer | ||
| Brian Rini, MD | |||
| Consulting; Membership on advisory committee or review panels: | Genentech; Novartis; Pfizer; Wyeth | ||
| Christopher Wood, MD | |||
| Consulting; Teaching & Speaking: | Ethicon; Pfizer | ||
The following faculty has indicated he/she has no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:
Tsung Wen Chong, MD
This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and UNITECH Communications®.
